Jordi Fortuny-Profitos

Mr. Jordi Fortuny-Profitos

ARCVI
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Jorge Monserrat SanzJorge Monserrat Sanz
Jorge Monserrat Sanz
AGAna Gómez-Lahoz
Ana Gómez-Lahoz
Miguel A. OrtegaMiguel A. Ortega
Miguel A. Ortega
JSJOSÉ SANZ-MORENO
JOSÉ SANZ-MORENO
BMBenjamin Muñoz
Benjamin Muñoz
OGon behalf of the COVID-19 HUPA Group
on behalf of the COVID-19 HUPA Group
SARS-CoV-2 is a new coronavirus characterized by a high infection and transmission capacity. A significant number of patients develop inadequate immune responses that produce massive releases of cytokines that compromise their survival. Soluble factors are clinically and pathologically relevant in COVID-19 survival but remain only partially characterized. The objective of this work was to simultaneously study 62 circulating soluble factors, including innate and adaptive cytokines and their soluble receptors, chemokines and growth and wound-healing/repair factors, in severe COVID-19 patients who survived compared to those with fatal outcomes. Serum samples were obtained from 286 COVID-19 patients and 40 healthy controls. The 62 circulating soluble factors were quantified using a Luminex Milliplex assay. Results. The patients who survived had decreased levels of the following 30 soluble factors of the 62 studied compared to those with fatal outcomes, therefore, these decreases were observed for cytokines and receptors predominantly produced by the innate immune system—IL-1α, IL-1α, IL-18, IL-15, IL-12p40, IL-6, IL-27, IL-1Ra, IL-1RI, IL-1RII, TNFα, TGFα, IL-10, sRAGE, sTNF-RI and sTNF-RII—for the chemokines IL-8, IP-10, MCP-1, MCP-3, MIG and fractalkine; for the growth factors M-CSF and the soluble receptor sIL2Ra; for the cytokines involved in the adaptive immune system IFNγ, IL-17 and sIL-4R; and for the wound-repair factor FGF2. On the other hand, the patients who survived had elevated levels of the soluble factors TNFβ, sCD40L, MDC, RANTES, G-CSF, GM-CSF, EGF, PDGFAA and PDGFABBB compared to those who died. Conclusions. Increases in the circulating levels of the sCD40L cytokine; MDC and RANTES chemokines; the G-CSF and GM-CSF growth factors, EGF, PDGFAA and PDGFABBB; and tissue-repair factors are strongly associated with survival. By contrast, large increases in IL-15, IL-6, IL-18, IL-27 and IL-10; the sIL-1RI, sIL1RII and sTNF-RII receptors; the MCP3, IL-8, MIG and IP-10 chemokines; the M-CSF and sIL-2Ra growth factors; and the wound-healing factor FGF2 favor fatal outcomes of the disease.

Verified
Journal Article
Open access
PDF file
Melchor AlvarezMelchor Alvarez
Melchor Alvarez
Miguel A. OrtegaMiguel A. Ortega
Miguel A. Ortega
ÓGÓscar Gasulla
Óscar Gasulla
JFJordi Fortuny-Profitos
Jordi Fortuny-Profitos
FMferran A. Mazaira mazaira
ferran A. Mazaira mazaira
AAAngel Asúnsolo
Angel Asúnsolo
This study aimed to create an individualized analysis model of the risk of intensive care unit (ICU) admission or death for coronavirus disease 2019 (COVID-19) patients as a tool for the rapid clinical management of hospitalized patients in order to achieve a resilience of medical resources. This is an observational, analytical, retrospective cohort study with longitudinal follow-up. Data were collected from the medical records of 3489 patients diagnosed with COVID-19 using RT-qPCR in the period of highest community transmission recorded in Europe to date: February–June 2020. The study was carried out in in two health areas of hospital care in the Madrid region: the central area of the Madrid capital (Hospitales de Madrid del Grupo HM Hospitales (CH-HM), n = 1931) and the metropolitan area of Madrid (Hospital Universitario Príncipe de Asturias (MH-HUPA) n = 1558). By using a regression model, we observed how the different patient variables had unequal importance. Among all the analyzed variables, basal oxygen saturation was found to have the highest relative importance with a value of 20.3%, followed by age (17.7%), lymphocyte/leukocyte ratio (14.4%), CRP value (12.5%), comorbidities (12.5%), and leukocyte count (8.9%). Three levels of risk of ICU/death were established: low-risk level (20%). At the high-risk level, 13% needed ICU admission, 29% died, and 37% had an ICU–death outcome. This predictive model allowed us to individualize the risk for worse outcome for hospitalized patients affected by COVID-19.

12 November 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Jorge Monserrat SanzJorge Monserrat Sanz
Jorge Monserrat Sanz
AAAngel Asúnsolo
Angel Asúnsolo
AGAna Gómez-Lahoz
Ana Gómez-Lahoz
Miguel A. OrtegaMiguel A. Ortega
Miguel A. Ortega
JGJose Maria Gasalla
Jose Maria Gasalla
Melchor AlvarezMelchor Alvarez
Melchor Alvarez
Objective: To describe the capacity of a broad spectrum of cytokines and growth factors to predict ICU admission and/or death in patients with severe COVID-19. Design: An observational, analytical, retrospective cohort study with longitudinal follow-up. Setting: Hospital Universitario Príncipe de Asturias (HUPA). Participants: 287 patients diagnosed with COVID-19 admitted to our hospital from 24 March to 8 May 2020, followed until 31 August 2020. Main outcome measures: Profiles of immune response (IR) mediators were determined using the Luminex Multiplex technique in hospitalized patients within six days of admission by examining serum levels of 62 soluble molecules classified into the three groups: adaptive IR-related cytokines (n = 19), innate inflammatory IR-related cytokines (n = 27), and growth factors (n = 16). Results: A statistically robust link with ICU admission and/or death was detected for increased serum levels of interleukin (IL)-6, IL-15, soluble (s) RAGE, IP10, MCP3, sIL1RII, IL-8, GCSF and MCSF and IL-10. The greatest prognostic value was observed for the marker combination IL-10, IL-6 and GCSF. Conclusions: When severe COVID-19 progresses to ICU admission and/or death there is a marked increase in serum levels of several cytokines and chemokines, mainly related to the patient’s inflammatory IR. Serum levels of IL-10, IL-6 and GCSF were most prognostic of the outcome measure.

10 December 2020 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Jordi Fortuny-SantosJordi Fortuny-Santos
Jordi Fortuny-Santos
PRPatxi Ruiz-de-Arbulo-López
Patxi Ruiz-de-Arbulo-López
LCLluís Cuatrecasas-Arbós
Lluís Cuatrecasas-Arbós
JFJordi Fortuny-Profitos
Jordi Fortuny-Profitos
While multi-model assembly lines are used by advanced lean companies because of their flexibility (different models of a product are produced in small lots and reach the customers in a short lead time), most of the extant literature on how to staff assembly lines focuses either on single-model lines or on mixed-model lines. The literature on multi-model lines is scarce and results given by current methods may be of limited applicability. In consequence, we develop a procedure to staff multi-model assembly lines while taking into account the principles of lean manufacturing. As a first approach, we replace the concepts of operation time and desired cycle time by their reciprocal magnitudes workload and capacity, and we define the dimensionless term of unit workload (load/capacity ratio) in order to avoid magnitudes related to time such as cycle time because, in practice, they might not be known. Next, we develop the necessary equations to apply this framework to a multi-model line. Finally, a piece of software in Python is developed, taking advantage of Google’s OR-Tools solver, to achieve an optimal multi-model line with a constant workforce and with each workstation performing the same tasks across all models. Several instances are tested to ensure the performance of this method.